Gilgamesh Pharma, a clinical-stage neuroscience company focused on transforming psychiatric treatment, today announced ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window An ...

HAMBURG, Germany, May 18, 2011 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) and Roche (SWX:RO) (SWX:ROG) (OTCQX:RHHBY) today decided to voluntarily terminate the first proof-of-concept study ...

A comparative analysis of inpatient Do Not Resuscitate (DNR) forms used at National Cancer Institute-designated cancer centers (NCICC) No significant financial relationships to disclose. This is an ...

The FDA approved combination dextromethorphan and bupropion extended-release tablets (Auvelity) for adults with major depressive disorder (MDD), Axsome Therapeutics announced on Friday.

Drugs that act on NMDA (N-methyl-D-aspartate) receptors, which are essential for learning, memory and moment-by-moment consciousness, are key for treating neuropsychiatric disorders. These drugs were ...

Cough-focused biotech Seyltx has secured the option to license a portfolio of eight GluN2B antagonists from NeurOp, including one candidate that has completed a phase 1 trial. The drugs are all ...

Despite growing off-label use, ketamine and related NMDA blockers show no reliable evidence of easing chronic pain, highlighting the urgent need for safer and more effective treatments. Review: ...

YONGIN, South Korea--(BUSINESS WIRE)--GNT Pharma Inc. today reports positive top-line results from a phase II, double-blind, randomized, placebo-controlled, multi-center study assessing the safety and ...

ATLANTA--(BUSINESS WIRE)--NeurOp, Inc., a clinical-stage biotechnology company focused on neurological and psychiatric disorders, today announced that the U.S. Food and Drug Administration (FDA) has ...